The human monoclonal anti-CTLA-4 IgG1 antibody Ipilimumab (Yervoy, MDX-010) was, as described above, FDA approved in 2011 for the treatment of metastatic melanoma [75]. The gene discussed is CTLA4; the disease is metastatic melanoma.